Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2

Cancer Research

Volumn 56, Issue 10, 1996, Pages 2361-2367

  McLaughlin, Joanne P ^a   Schlom, Jeffrey ^a   Kantor, Judy A ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; RECOMBINANT INTERLEUKIN 2; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNIZATION; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR IMMUNOLOGY; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SMALLPOX VACCINE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 0029884292     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Erard, F., Corthesy, P., Nabolz, M., Lowenthal, J. W., Zaech, P., Plaetinck, G., and MacDonald, H. R. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J. Immunol., 134: 1644-1652, 1985.
2. Henney, C. S., Kuribayashi, K., Kern, D. E , and Gillis, S. Interleukin-2 augments natural killer cell activity. Nature (Lond.), 268: 154-156, 1977.
3. Farrar, W J , Johnson, H. M., and Farrar, J. J. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J. Immunol., 126. 1120-1125, 1981.
4. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh tumour cells by interleukin-2-activated autologous human peripheral blood lymphocytes J. Exp Med., 155: 1823-1841, 1982
5. Wagner, H., Hardt, C., Heeg, K , Pfizenmaier, K., Stotter, H., and Rollinghoff, M. The in vivo effects of interleukin 2 (TCGF). Immunobiology, 161: 139-156, 1982.
6. Hefeneider, S H., Conlon, P. J., Henney, C S , and Gillis, S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J. Immunol., 130. 222-227, 1983.
7. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Lineham, W. M , and Seipp, C. A. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474-484, 1989.
8. Bukowski, R. M., Goodman, P , Crawford, E D., Sergi, J. S., Rodman, B. G., and Whitehead, R. P. Phase II trial of high-dose intermittent interleukin-2 in renal cell carcinoma: a Southwest Oncology Group study. J. Natl. Cancer Inst., 24: 143-146, 1990.
9. Parkinson, D. R., Abrams, J S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., van Echo, D. A , Snzol, M , Dutcher, J P., Aronson, F R., Doroshow, J. H., Atkins, M. B., and Hawkins, M. J. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol., 8: 1650-1656, 1990.
10. Chang, A. E , Yoshizawa, H , Sakai, K., Cameron, M. J., Sondak, V. K., and Shu, S Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res., 53: 1043-1050, 1993.
11. Weinberg, A., and Merigan, T. C. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection J. Immunol., 140: 294-299, 1988.
12. Perrin, P., Joffret, M. L., Zanetti, C., Leclerc, C., Oth, D., Sureau, P., and Thibodeau, L. Interleukin 2 increases protection against experimental rabies Immunobiology, 177: 199-209, 1988.
13. Schijns, V E., Claassen, I. J., Vermeulen, A. A , Horzinek, M. C., and Osterhaus, A. D. Modulation of antiviral immune responses by exogenous cytokines: effects of tumor necrosis factor-α, interleukin-1α, interleukin-2 and interferon-γ on the immunogenicity of an inactivated rabies vaccine J Gen. Virol., 75: 55-63, 1994.
14. Reddy, D N., Reddy, P. G., Xue, W., Minocha, H. C., Daley, M. J., and Blecha, F. Immunopotentiation of bovine respiratory disease virus vaccines by interleukin-1β and interleukin-2. Vet. Immunol. Immunopathol , 37. 25-38, 1993
15. McCullough, K. C , Pullen, L , and Parkinson, D. The immune response against foot-and-mouth disease virus: influence of the T lymphocyte growth factors IL-1 and IL-2 on the murine humoral response in vivo. Immunol Lett., 31: 41-46, 1991
16. Good, M. F., Pombo, D., Lunde, M. N., Maloy, W. L., Halenbeck, R., Koths, K., Miller, L. H., and Berzofsky, J. A. Recombinant human IL-2 overcomes genetic non-responsiveness to malaria sporozoite peptides, correlation of effect with biologic activity of IL-2. J. Immunol., 141: 972-977, 1988.
17. Hughes, H. P. A., Campos, M., van Drunen Littel-van den Hurk, S., Zamb, T., Sordillo, L. M., Godson, D., and Babiuk, L A Multiple administrations with interleukin-2 potentiates antigen specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV. Vaccine, 10: 226-230, 1992.
18. Perrin, P., Joffret, M. L., Zanetti, C., Leclerc, C., Oth, D., Sureau, P , and Thibodeau, L Interleukin 2 increases protection against experimental rabies. Immunobiol., 177: 199-209, 1988.
19. Reddy, P. G , Blecha, F , Minocha, H. C , Anderson, G. A., Morrill, J L , Fedorka-Cray, P. J., and Baker, P E. Bovine recombinant interleukin-2 augments immunity and resistance to bovine herpesvirus infection. Vet. Immunol. Immunopathol., 23: 61-74, 1989.
20. Provinciali, M., Di Stefano, G., Colombo, M., Croce, F., Gandolfi, M. C., Daghetta, L , Anichini, M., DellaBitta, R., and Fabris, N. Adjuvant effects of low dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects Mech. Aging Dev , 77: 75-82, 1994.
21. Arroyo, P. J., Bash, J. A., and Wallack, M K. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model. Cancer Immunol. Immunother., 31: 305-311, 1990.
22. Barnavon, T., Iwaki, H , Bash, J. A., Brettschneider, F., Hilsenbeck, S., Darnell, A. S., and Wallack, M. K. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J. Surg. Res., 45. 523-530, 1988.
23. Sivanandham, M., Scoggin, S. D., Tanaka, N., and Wallack, M. K. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studies in a synergetic CC-36 murine colon hepatic metastasis model. Cancer Immunol. Immunother., 38: 259-264, 1994.
24. Ahlert, T Tumor cell vaccination and IL-2 therapy. Hybridoma, 12: 549-552, 1993.
25. Bronte, V., Tsung, K , Rao, J. B , Chen, P. W , Wang, M., Rosenberg, S. A., and Restifo, N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases J Immunol., 154: 5282-5292, 1995.
26. Zimmerman, W., Weber, B., Ortlieb, B., Rudert, F., Schempp, W., Fiebig, H H., Shively, J. E , von Kleist, S., and Thompson, J A Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tissues Cancer Res , 48: 2443-2550, 1988.
27. Robbins, P. F., Kantor, J., Salgaller, M., Horan Hand, P., Fernsten, P D., and Schlom, J. Transduction and expression of the human carcinoembryonic antigen (CEA) gene in a murine colon carcinoma cell line. Cancer Res., 51: 3757-3662, 1991.
28. Horan Hand, P., Robbins, P F , Salgaller, M. L , Poole, D. J., and Schlom, J. Evaluation of human carcinoembryonic antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol. Immunother., 36: 65-75, 1993.
29. Kaufman, H., Schlom, J , and Kantor, J A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer, 48 900-907, 1991.
30. Kantor, J., Irvine, K , Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J Antitumor activity and immune response induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst., 84 1084-1091, 1992.
31. Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R. Greiner, J., Kaufman, H , Eggensperger, D., and Schlom, J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate Cancer Res., 52: 6917-6925, 1992.
32. Tsang, K. Y , Zaremba, S., Nieroda, C A., Zhu, M. Z., Hamilton, J. M , and Schlom, J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
33. Conry, R M , Saleh, M N., Schlom, J., and LoBugho, A. F. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus in man. Proc. Am. Assoc. Cancer Res., 36. 492, 1995.
34. Muraro, R., Wunderlich, D., Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. Definition of monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinoma versus normal adult tissues. Cancer Res., 45: 5769-5780, 1985
35. Gillis, S., Ferm, M. M., Ou, W., and Smith, K. A. T cell growth factor parameters of production and a quantitative microassay for activity. J. Immunnol , 120: 2027-2032, 1978
36. Rosenberg, S A., Spiess, P. J., and Schwarz, S. In vivo administration of interleukin-2 specific alloimmune responses. Transplantation (Baltimore), 35: 631-634, 1982.
37. Mosmann, T R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol , 136: 2348-2357, 1986.
38. Kundig, T. M., Bachmann, M. A., Lefrancois, L., Puddington, L., Hengartner, H., and Zinkernagel, R. M. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J. Immunol., 150: 4450-4456, 1993
39. Hodge, J. W., McLaughlin, J. P., Abrams , S. I , Shupert, W L., Schlom, J., and Kantor, J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity Cancer Res , 55: 3598-3603, 1995.